Core Insights - TELA Bio, Inc. achieved a 16% full-year revenue growth and record fourth-quarter results despite a significant rebuild of its commercial organization [5] - The company attributes its performance to strong adoption in Europe and continued momentum in its IHR, LPR, and LiquiFix product lines [5] - A strategic shift to a 'deep and narrow' geographic strategy has been implemented, focusing on high-volume institutions to cultivate multiple users per site [5] Financial Performance - The hernia business mix transitioned from 70% ventral to 50%, with notable growth in inguinal and hiatal procedures driven by robotic surgery adoption [5] - The company maintained operating discipline and improved leverage, using savings to fund increased customer education and training events [5] - TELA Bio anticipates at least 8% revenue growth for the full year 2026, adopting a cautious approach due to the restructuring of the sales force [5][7] Strategic Priorities - A full market launch of a long-term resorbable OviTex product is planned for April 1, 2026, to compete with biosynthetic alternatives [5] - The focus for 2026 will be on 'contract execution,' translating existing agreements into active clinical usage and revenue [5] - Plans to expand European presence into Continental markets and introduce the PRS portfolio outside the U.S. by late 2026 or early 2027 [5] Operational Changes - The U.S. commercial leadership has been restructured to implement a General Manager structure, bringing decision-making closer to local customers [5] - Identified Q1 headwinds include severe January weather affecting elective procedures and temporary disruptions from splitting sales territories [5] - While unit growth remains high at 22% in hernia, average selling prices (ASPs) are impacted by a shift towards smaller units used in robotic and laparoscopic procedures [5] Financial Flexibility - The company upsized its debt facility and raised equity capital in late 2025 to ensure financial flexibility during the commercial transition [5]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 increased 18% year-over-year to $20.9 million, and full-year revenue grew 16% to $80.3 million [24] - OviTex revenue grew 12% and OviTex PRS grew 20% for the year, with OviTex unit sales increasing 20% for the quarter and 22% for the year [24] - Gross margin improved to 66% for Q4 and 68% for the full year, compared to 64% and 67% in the prior year periods [25] - Net loss was $9 million in Q4 and $38.8 million for the full year, compared to $9.2 million and $37.8 million in the prior year periods [27] Business Line Data and Key Metrics Changes - LiquiFix revenue more than tripled over Q4 2024, indicating early commercial traction [24] - European sales accounted for 15% of total revenue, increasing 17% from $10.3 million in 2024 to $12.1 million in 2025 [25] - Sales and marketing expenses were $14.5 million in Q4 and $63.2 million for the full year, reflecting increased commissions due to stronger revenue [26] Market Data and Key Metrics Changes - The U.S. commercial organization underwent significant changes, with a focus on improving talent and processes to drive growth [5][7] - The company is seeing strong demand in hernia repair and plastic reconstructive surgery markets, with no signs of diminished opportunity [5] Company Strategy and Development Direction - The company aims to sustain momentum from 2025 and achieve further sales growth in the U.S. and Europe through improved talent and commercial leadership [7] - A focus on product innovation is central to the company's strategy, with plans for additional product launches throughout the year [8] - The company is investing in expanding its presence in continental Europe, viewing it as a meaningful contributor to future growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the new commercial foundation and the potential for sustained growth, despite the challenges of integrating new sales reps [12][22] - The company anticipates revenue growth of at least 8% over 2025, with Q1 2026 revenue expected to be approximately $18.5 million [28] - Management acknowledged the complexities of contract execution and the need for time to mature the new sales team [40][41] Other Important Information - The company launched OviTex LTR, a new product offering, and enrolled patients in a hiatal hernia trial to strengthen clinical evidence [10] - The company has upgraded its board of directors to include new expertise [11] Q&A Session Summary Question: Guidance for fiscal year top line growth - Management explained the cautious guidance of at least 8% growth due to the significant changes in the organization and the need for new reps to mature [36][38] Question: Contracting and execution expectations - Management highlighted the focus on executing existing contracts and the complexity involved in the contracting process [48][49] Question: Q1 guidance and external factors - Management noted that Q1 performance was impacted by external factors such as weather and market conditions, but emphasized the focus on controllable factors like hiring and training [87][88] Question: Long-term growth outlook - Management expressed confidence in returning to double-digit growth rates once the organization stabilizes and new products are launched [62][63]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 increased 18% year-over-year to $20.9 million, and full-year revenue grew 16% to $80.3 million [24] - Gross margin improved to 66% for Q4 and 68% for the full year, compared to 64% and 67% in the prior year periods [25] - Net loss was $9 million in Q4 and $38.8 million for the full year, compared to $9.2 million and $37.8 million in the prior year periods [27] Business Line Data and Key Metrics Changes - Revenue from OviTex grew 12% and OviTex PRS grew 20% for the year, with OviTex unit sales increasing 20% for the quarter and 22% for the year [24] - LiquiFix revenue more than tripled over Q4 2024, indicating early commercial traction [24] - PRS unit sales grew 12% for both the quarter and the year [24] Market Data and Key Metrics Changes - European sales accounted for 15% of total revenue or $12.1 million in 2025, a 17% increase from $10.3 million in 2024 [25] - The company is seeing rapid adoption of OviTex in the U.K. and the Netherlands, winning share based on patient preference and product efficacy [10] Company Strategy and Development Direction - The company is focused on sustaining momentum achieved in 2025 and aims for further U.S. and European sales growth through improved talent and processes [8] - A strategic investment plan is in place to expand presence within continental Europe, which is seen as a meaningful contributor to growth [11] - Product innovation remains a core focus, with additional product launches anticipated throughout the year [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the new commercial foundation laid in 2025 and the potential for sustainable growth moving forward [8] - The company anticipates revenue growth of at least 8% over 2025, with Q1 2026 revenue expected to be approximately $18.5 million [27] - Management acknowledged the challenges of transitioning to a new commercial structure but emphasized the commitment to operational discipline and customer service [12] Other Important Information - The company reinforced and upsized its debt facility, strengthening its balance sheet for future growth [11] - A new Chief Medical Officer was appointed to drive surgeon awareness and support clinical education [9] Q&A Session Summary Question: Guidance for fiscal year top line growth - Management explained the guidance was set conservatively due to the significant changes implemented and the need for new reps to mature [36][41] Question: Contracting and execution expectations - Management highlighted the focus on executing existing contracts and the complexity involved in contract implementation [47][49] Question: Q1 guidance specifics - Management noted that typical seasonality and territory restructuring contributed to a slow start in Q1 [52][54] Question: Confidence in back half of the year - Management expressed confidence in achieving growth due to a fully staffed sales force and new product launches [89][90]